Angiotensin type 2 receptor in resistance arteries of type 2 diabetic hypertensive patients

Carmine Savoia, Rhian M. Touyz, Massimo Volpe, Ernesto L. Schiffrin

Research output: Contribution to journalArticle

94 Citations (Scopus)

Abstract

The role of angiotensin type 2 receptor (AT2R) on vascular responses to angiotensin II in humans remains unclear. In this study we explored whether AT2R is expressed and functionally active on peripheral resistance arteries of hypertensive diabetic patients treated for 1 year with either the angiotensin receptor blocker valsartan or the β-blocker atenolol. Twenty-six hypertensive type 2 diabetic patients treated with oral hypoglycemic and antihypertensive agents (not receiving angiotensin receptor blockers or β-blockers) were randomly assigned to double-blind treatment for 1 year with valsartan or atenolol once daily added to their previous therapy in a clinical trial that we reported recently and compared with 10 normal subjects. Resistance arteries dissected from gluteal subcutaneous tissues were assessed on a pressurized myograph. Vasomotor response curves to angiotensin II (1 nmol/L to 1 μmol/L) were performed on norepinephrine precontracted vessels in the presence of valsartan (10 μmol/L) with or without the AT2R inhibitor PD123319 (1 μmol/L). AT2R expression was evaluated by confocal microscopy. After 1 year of treatment, systolic and diastolic blood pressure was controlled and comparable in the valsartan and atenolol groups. Angiotensin II evoked a significant vasodilatory response only on resistance arteries from patients treated with valsartan, effect blocked by PD123319. AT2R expression was 4-fold higher in small arteries of valsartan-treated patients. In conclusion, AT2Rs are upregulated and contribute to angiotensin II-induced vasodilation in resistance arteries of hypertensive diabetic patients treated with angiotensin type 1 receptor blockers and may mediate, in part, vascular actions of these drugs in high cardiovascular risk patients.

Original languageEnglish
Pages (from-to)341-346
Number of pages6
JournalHypertension
Volume49
Issue number2
DOIs
Publication statusPublished - Feb 2007

Fingerprint

Valsartan
Angiotensin Type 2 Receptor
Arteries
Angiotensin II
Atenolol
Angiotensin Receptor Antagonists
Blood Vessels
Blood Pressure
Angiotensin II Type 1 Receptor Blockers
Subcutaneous Tissue
Hypoglycemic Agents
Confocal Microscopy
Vasodilation
Vascular Resistance
Antihypertensive Agents
Norepinephrine
Therapeutics
Clinical Trials

Keywords

  • Angiotensin receptors
  • AT receptor
  • Human hypertension
  • Resistance arteries
  • Type 2 diabetes

ASJC Scopus subject areas

  • Internal Medicine

Cite this

Angiotensin type 2 receptor in resistance arteries of type 2 diabetic hypertensive patients. / Savoia, Carmine; Touyz, Rhian M.; Volpe, Massimo; Schiffrin, Ernesto L.

In: Hypertension, Vol. 49, No. 2, 02.2007, p. 341-346.

Research output: Contribution to journalArticle

Savoia, Carmine ; Touyz, Rhian M. ; Volpe, Massimo ; Schiffrin, Ernesto L. / Angiotensin type 2 receptor in resistance arteries of type 2 diabetic hypertensive patients. In: Hypertension. 2007 ; Vol. 49, No. 2. pp. 341-346.
@article{97b4282e772f41378b8458fe9fcbf474,
title = "Angiotensin type 2 receptor in resistance arteries of type 2 diabetic hypertensive patients",
abstract = "The role of angiotensin type 2 receptor (AT2R) on vascular responses to angiotensin II in humans remains unclear. In this study we explored whether AT2R is expressed and functionally active on peripheral resistance arteries of hypertensive diabetic patients treated for 1 year with either the angiotensin receptor blocker valsartan or the β-blocker atenolol. Twenty-six hypertensive type 2 diabetic patients treated with oral hypoglycemic and antihypertensive agents (not receiving angiotensin receptor blockers or β-blockers) were randomly assigned to double-blind treatment for 1 year with valsartan or atenolol once daily added to their previous therapy in a clinical trial that we reported recently and compared with 10 normal subjects. Resistance arteries dissected from gluteal subcutaneous tissues were assessed on a pressurized myograph. Vasomotor response curves to angiotensin II (1 nmol/L to 1 μmol/L) were performed on norepinephrine precontracted vessels in the presence of valsartan (10 μmol/L) with or without the AT2R inhibitor PD123319 (1 μmol/L). AT2R expression was evaluated by confocal microscopy. After 1 year of treatment, systolic and diastolic blood pressure was controlled and comparable in the valsartan and atenolol groups. Angiotensin II evoked a significant vasodilatory response only on resistance arteries from patients treated with valsartan, effect blocked by PD123319. AT2R expression was 4-fold higher in small arteries of valsartan-treated patients. In conclusion, AT2Rs are upregulated and contribute to angiotensin II-induced vasodilation in resistance arteries of hypertensive diabetic patients treated with angiotensin type 1 receptor blockers and may mediate, in part, vascular actions of these drugs in high cardiovascular risk patients.",
keywords = "Angiotensin receptors, AT receptor, Human hypertension, Resistance arteries, Type 2 diabetes",
author = "Carmine Savoia and Touyz, {Rhian M.} and Massimo Volpe and Schiffrin, {Ernesto L.}",
year = "2007",
month = "2",
doi = "10.1161/01.HYP.0000253968.95136.b8",
language = "English",
volume = "49",
pages = "341--346",
journal = "Hypertension",
issn = "0194-911X",
publisher = "Lippincott Williams and Wilkins",
number = "2",

}

TY - JOUR

T1 - Angiotensin type 2 receptor in resistance arteries of type 2 diabetic hypertensive patients

AU - Savoia, Carmine

AU - Touyz, Rhian M.

AU - Volpe, Massimo

AU - Schiffrin, Ernesto L.

PY - 2007/2

Y1 - 2007/2

N2 - The role of angiotensin type 2 receptor (AT2R) on vascular responses to angiotensin II in humans remains unclear. In this study we explored whether AT2R is expressed and functionally active on peripheral resistance arteries of hypertensive diabetic patients treated for 1 year with either the angiotensin receptor blocker valsartan or the β-blocker atenolol. Twenty-six hypertensive type 2 diabetic patients treated with oral hypoglycemic and antihypertensive agents (not receiving angiotensin receptor blockers or β-blockers) were randomly assigned to double-blind treatment for 1 year with valsartan or atenolol once daily added to their previous therapy in a clinical trial that we reported recently and compared with 10 normal subjects. Resistance arteries dissected from gluteal subcutaneous tissues were assessed on a pressurized myograph. Vasomotor response curves to angiotensin II (1 nmol/L to 1 μmol/L) were performed on norepinephrine precontracted vessels in the presence of valsartan (10 μmol/L) with or without the AT2R inhibitor PD123319 (1 μmol/L). AT2R expression was evaluated by confocal microscopy. After 1 year of treatment, systolic and diastolic blood pressure was controlled and comparable in the valsartan and atenolol groups. Angiotensin II evoked a significant vasodilatory response only on resistance arteries from patients treated with valsartan, effect blocked by PD123319. AT2R expression was 4-fold higher in small arteries of valsartan-treated patients. In conclusion, AT2Rs are upregulated and contribute to angiotensin II-induced vasodilation in resistance arteries of hypertensive diabetic patients treated with angiotensin type 1 receptor blockers and may mediate, in part, vascular actions of these drugs in high cardiovascular risk patients.

AB - The role of angiotensin type 2 receptor (AT2R) on vascular responses to angiotensin II in humans remains unclear. In this study we explored whether AT2R is expressed and functionally active on peripheral resistance arteries of hypertensive diabetic patients treated for 1 year with either the angiotensin receptor blocker valsartan or the β-blocker atenolol. Twenty-six hypertensive type 2 diabetic patients treated with oral hypoglycemic and antihypertensive agents (not receiving angiotensin receptor blockers or β-blockers) were randomly assigned to double-blind treatment for 1 year with valsartan or atenolol once daily added to their previous therapy in a clinical trial that we reported recently and compared with 10 normal subjects. Resistance arteries dissected from gluteal subcutaneous tissues were assessed on a pressurized myograph. Vasomotor response curves to angiotensin II (1 nmol/L to 1 μmol/L) were performed on norepinephrine precontracted vessels in the presence of valsartan (10 μmol/L) with or without the AT2R inhibitor PD123319 (1 μmol/L). AT2R expression was evaluated by confocal microscopy. After 1 year of treatment, systolic and diastolic blood pressure was controlled and comparable in the valsartan and atenolol groups. Angiotensin II evoked a significant vasodilatory response only on resistance arteries from patients treated with valsartan, effect blocked by PD123319. AT2R expression was 4-fold higher in small arteries of valsartan-treated patients. In conclusion, AT2Rs are upregulated and contribute to angiotensin II-induced vasodilation in resistance arteries of hypertensive diabetic patients treated with angiotensin type 1 receptor blockers and may mediate, in part, vascular actions of these drugs in high cardiovascular risk patients.

KW - Angiotensin receptors

KW - AT receptor

KW - Human hypertension

KW - Resistance arteries

KW - Type 2 diabetes

UR - http://www.scopus.com/inward/record.url?scp=33846427712&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33846427712&partnerID=8YFLogxK

U2 - 10.1161/01.HYP.0000253968.95136.b8

DO - 10.1161/01.HYP.0000253968.95136.b8

M3 - Article

C2 - 17159079

AN - SCOPUS:33846427712

VL - 49

SP - 341

EP - 346

JO - Hypertension

JF - Hypertension

SN - 0194-911X

IS - 2

ER -